STOK — Stoke Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$30.83
-$0.06 (-0.19%)
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ. It is led by Ian F. Smith A.C.A., C.P.A., based in 45 Wiggins Avenue, Bedford, MA, United States, 01730, with about 170 employees. Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest reported STOK revenue for 2025-09-30 was $10.6M. Net income was $51.0M. Revenue was down 23.1% from 2025-06-30 to 2025-09-30. STOK currently screens at market cap $1.88B.
Use this STOK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the STOK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the STOK SEC filings page. Lician reads the product cache first so this HTML stays unique to Stoke Therapeutics Inc even when a live quote feed is slow.
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Key Statistics
Market Cap
$1.88B
Volume
925,815
Previous Close
$33.46
Day Range
$32.57 – $33.55
P/B Ratio
4.77
EPS
-$1.65
Revenue
$36.55M
Net Income
-$88.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+316.3%
Profit Margin
-243.4%
Employees
170
STOK Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $36.55M | $8.78M | $12.40M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$88.98M | -$104.70M | -$101.07M | -$85.81M |
| EPS (Diluted) | -$1.65 | -$2.38 | -$2.60 | -$2.34 |
Total Assets
$271.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$127.98M
Operating Cash Flow
-$86.85M
Free Cash Flow
$0.00
Stoke Therapeutics Inc Company Information
- CEO & Director
- Ian F. Smith A.C.A., C.P.A.
- Headquarters
- 45 Wiggins Avenue, Bedford, MA, United States, 01730
- Website
- www.stoketherapeutics.com
- Phone
- 781 430 8200
- IPO / Founded
- 2019-06-19
- Sector
- Healthcare
- Industry
- Biotechnology